Applied DNA Sciences Inc PE Ratio 2010-2024 | APDN
Current and historical p/e ratio for Applied DNA Sciences Inc (APDN) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Applied DNA Sciences Inc PE ratio as of May 02, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Applied DNA Sciences Inc PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-05-02 | 0.89 | 0.00 | |
| 2024-12-31 | 10.20 | $-286.00 | 0.00 |
| 2024-09-30 | 32.49 | $-348.00 | 0.00 |
| 2024-06-30 | 20.42 | $-592.00 | 0.00 |
| 2024-03-31 | 410.00 | $-855.50 | 0.00 |
| 2023-12-31 | 616.80 | $-540.00 | 0.00 |
| 2023-09-30 | 1210.00 | $-750.00 | 0.00 |
| 2023-06-30 | 1290.00 | $-490.00 | 0.00 |
| 2023-03-31 | 1130.00 | $-380.00 | 0.00 |
| 2022-12-31 | 1660.00 | $-660.00 | 0.00 |
| 2022-09-30 | 1130.00 | $-990.00 | 0.00 |
| 2022-06-30 | 738.20 | $-1,590.00 | 0.00 |
| 2022-03-31 | 2140.00 | $-1,920.00 | 0.00 |
| 2021-12-31 | 4020.00 | $-1,900.00 | 0.00 |
| 2021-09-30 | 5390.00 | $-2,150.00 | 0.00 |
| 2021-06-30 | 6790.00 | $-2,370.00 | 0.00 |
| 2021-03-31 | 7190.00 | $-2,630.00 | 0.00 |
| 2020-12-31 | 5100.00 | $-3,210.00 | 0.00 |
| 2020-09-30 | 7730.00 | $-3,450.00 | 0.00 |
| 2020-06-30 | 8070.00 | $-4,070.00 | 0.00 |
| 2020-03-31 | 4020.00 | $-4,950.00 | 0.00 |
| 2019-12-31 | 4190.00 | $-7,360.00 | 0.00 |
| 2019-09-30 | 8940.00 | $-10,640.00 | 0.00 |
| 2019-06-30 | 20000.00 | $-14,000.00 | 0.00 |
| 2019-03-31 | 28500.00 | $-16,400.00 | 0.00 |
| 2018-12-31 | 16000.00 | $-16,000.00 | 0.00 |
| 2018-09-30 | 59600.00 | $-16,400.00 | 0.00 |
| 2018-06-30 | 50400.00 | $-15,600.00 | 0.00 |
| 2018-03-31 | 57600.00 | $-15,600.00 | 0.00 |
| 2017-12-31 | 63600.00 | $-18,000.00 | 0.00 |
| 2017-09-30 | 114800.00 | $-19,600.00 | 0.00 |
| 2017-06-30 | 70400.00 | $-19,600.00 | 0.00 |
| 2017-03-31 | 66000.00 | $-21,200.00 | 0.00 |
| 2016-12-31 | 74000.00 | $-21,600.00 | 0.00 |
| 2016-09-30 | 122000.00 | $-20,400.00 | 0.00 |
| 2016-06-30 | 129200.00 | $-17,200.00 | 0.00 |
| 2016-03-31 | 137600.00 | $-14,800.00 | 0.00 |
| 2015-12-31 | 129600.00 | $-13,600.00 | 0.00 |
| 2015-09-30 | 204800.00 | $-28,800.00 | 0.00 |
| 2015-06-30 | 124000.00 | $-34,400.00 | 0.00 |
| 2015-03-31 | 103600.00 | $-31,200.00 | 0.00 |
| 2014-12-31 | 115600.00 | $-26,800.00 | 0.00 |
| 2014-09-30 | 218399.00 | $-30,352.10 | 0.00 |
| 2014-06-30 | 293039.00 | $-23,952.10 | 0.00 |
| 2014-03-31 | 302399.00 | $-23,952.10 | 0.00 |
| 2013-12-31 | 390479.00 | $-23,952.10 | 0.00 |
| 2013-09-30 | 215999.00 | $-23,952.10 | 0.00 |
| 2013-06-30 | 479998.00 | $-23,952.10 | 0.00 |
| 2013-03-31 | 549598.00 | $-23,952.10 | 0.00 |
| 2012-12-31 | 503998.00 | $-23,952.10 | 0.00 |
| 2012-09-30 | 609598.00 | 0 | 0.00 |
| 2012-06-30 | 120000.00 | $-23,952.10 | 0.00 |
| 2012-03-31 | 142799.00 | $-47,904.20 | 0.00 |
| 2011-12-31 | 143999.00 | $-71,856.30 | 0.00 |
| 2011-09-30 | 132000.00 | $-71,856.30 | 0.00 |
| 2011-06-30 | 143759.00 | $-71,856.30 | 0.00 |
| 2011-03-31 | 136799.00 | $-71,856.30 | 0.00 |
| 2010-12-31 | 134400.00 | $-71,856.30 | 0.00 |
| 2010-09-30 | 110400.00 | $-95,808.40 | 0.00 |
| 2010-06-30 | 139199.00 | $-71,856.30 | 0.00 |
| 2010-03-31 | 167999.00 | $-71,856.30 | 0.00 |
| 2009-12-31 | 148799.00 | $47,903.80 | 3.11 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Industrial Products | PROTECTION-SFTY | $0.001B | $0.003B |
| Applied DNA Sciences, Inc. provides proprietary DNA-embedded biotechnology security solutions, using non-human DNA, that verify authenticity and protect corporate and government agencies from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion. They develop, market, and sub-license DNA security systems, supply-chain management systems and anti-counterfeit solutions. Applied DNA Sciences has an exclusive licensing and partnership agreement covering North America and Europe with Biowell Technology, Inc. of Taiwan. | |||